plozalizumab (TAK-202) / Takeda  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
plozalizumab (TAK-202) / Takeda
NCT02426021: Phase 1 Single Subcutaneous Dose Study of MLN1202

Withdrawn
1
0
Japan
MLN1202, MLN1202 Placebo
Takeda
Healthy Japanese and Caucasian Male Adults
11/15
11/15
NCT02723006: Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Terminated
1
22
US
TAK-580, MLN2480, TAK-202, MLN1202, plozalizumab, vedolizumab, Entyvio, nivolumab, Opdivo, ipilimumab, Yervoy
Millennium Pharmaceuticals, Inc.
Melanoma
05/18
05/18

Download Options